Arnstein, Hoyes and Lucchino to join board

CAMBRIDGE, MA (March 27, 2012) – MassBio members today elected a new chairman and three new board members at the 2012 MassBio Annual Meeting.

Geoff MacKay, president and CEO of Canton-based regenerative medicine company Organogenesis Inc., was elected board chairman for a two-year term. MacKay has served as president and CEO of Organogenesis since 2003 and provides significant global, commercial experience spanning the pharmaceutical and biotechnology sectors. He has been specifically involved in the emerging field of regenerative medicine for the last decade.

“Geoff has long been a champion and an advocate for the biotechnology industry in Massachusetts and we look forward to his vision for the future of the industry association,” Robert K. Coughlin, President & CEO of MassBio.

Joining the board this year are Caren Arnstein, senior vice president and Head of Communications for Genzyme, James Hoyes, President of EMD Serono, Inc., and David L. Lucchino, CEO of Semprus BioSciences.

“We are honored to add three such prestigious names and organizations to our Board of Directors, with each reinforcing a piece MassBio’s commitment to the industry here in Massachusetts,” Coughlin said. “Caren has worked in the industry in Massachusetts for nearly two decades years and represents a true homegrown success story in Genzyme. Jim’s experience over his career—especially his expertise in industry partnerships—bring us strength in one of the hottest topics in industry. And David’s tenure as co-founder of an innovative emerging growth company spun out of MIT represents the Greater Boston area’s commitment to cutting edge medical technology innovation. With these elections we emphasize our mission to be a voice for the totality of the industry in Massachusetts.”

The 2012-2013 members of the MassBio Executive Committee are:

Chair               Geoff MacKay, Organogenesis Inc.

Vice Chair       Glenn Batchelder, Civitas Therapeutics

Treasurer        Michael O'Hara, Deloitte

Clerk               Abbie Celniker, Eleven Biotherapeutics

Past Chair       Geoffrey Cox, Red Sky Partners

The 2012-2013 members of the MassBio Board of Directors are:

Caren Arnstein, Genzyme

Mark Bamforth, Gallus Biopharmaceuticals

Margaret Chu-Moyer, Amgen

Jeffrey Elton, Accenture

Scott Gillis, Onsite Therapeutics

Steven Gilman, Cubist Pharmaceuticals

Jose Carlos Gutierrez-Ramos, Pfizer

John Harrington, sanofi

John Hennessy, AstraZeneca R&D Boston

James Hoyes, EMD Serono

Peter Isakson, Abbott Laboratories

Edwin Kania, Flagship Ventures

Laurie Bartlett Keating, Millennium: The Takeda Oncology Company

Mark Leuchtenberger, Rib-X Pharmaceuticals

David Lucchino, Semprus BioSciences

Deanna Petersen, Shire Pharmaceuticals

David Reif, AstraZeneca R&D Boston

Steven Richter, Microtest Laboratories

Amit Sachdev, Vertex Pharmaceuticals

Frank Thomas, AMAG Pharmaceuticals

Kathleen Tregoning, Biogen Idec

Charles Wilson, Novartis

Lawrence Wittenberg, Goodwin Procter

Bill McDermott, McDermott, Quilty & Miller

Robert Gottlieb, RMG Associates